文献速递消化系统肿瘤

SARAH研究:90Y树脂微球SIRT对比索拉非尼治疗局部晚期不可手术肝细胞癌的疗效与安全性

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-10-26

SARAH是一项在法国25个中心开展的开放标签随机对照3期试验,纳入467例局部晚期或不可手术肝细胞癌患者,比较90Y树脂微球选择性内放疗(SIRT)与索拉非尼的疗效和安全性。两组严重不良事件发生率相似,但毒性谱不同。

要点

  • SIRT组严重不良事件77%,索拉非尼组82%,但索拉非尼腹泻和手足皮肤反应更常见。
  • 对于TACE失败后的局部晚期肝细胞癌,两种治疗均可选,生活质量和耐受性可辅助决策。

核心结论

  • 在局部晚期或中期肝细胞癌TACE失败后患者中,SIRT与索拉非尼的总生存无显著差异。
  • 生活质量和耐受性可能有助于在两种治疗间进行选择。

研究设计与样本

  • SARAH为多中心、开放标签、随机对照、研究者发起的3期试验,在法国25个肝脏疾病中心开展。
  • 纳入467例患者,随机1:1分配至SIRT组(237例)或索拉非尼组(222例),按中心、ECOG评分、既往TACE和宏观血管侵犯分层。
  • 主要终点为总生存,按意向治疗人群分析;安全性在至少接受一剂索拉非尼或至少一次SIRT检查的患者中评估。

主要发现

  • SIRT组226例中174例(77%)报告至少一次严重不良事件,索拉非尼组216例中176例(82%)。
  • 最常见的3级及以上治疗相关不良事件:疲乏(SIRT 9% vs 索拉非尼19%)、腹泻(1% vs 14%)、手足皮肤反应(<1% vs 6%)。
  • SIRT组19例死亡、索拉非尼组12例死亡被认为与治疗相关。

关键数值与推荐

  • 纳入标准:年龄≥18岁,预期寿命>3个月,ECOG 0-1,Child-Pugh A或B评分≤7,局部晚期肝细胞癌(BCLC C期)或不可手术/移植/消融的新发肝癌或TACE两次失败后的肝癌。
  • 索拉非尼用法:持续口服400 mg每日两次;SIRT在随机分组后2-5周进行。

临床怎么用

  • 对于TACE失败后的局部晚期肝细胞癌,SIRT和索拉非尼均可作为治疗选择,需综合评估生活质量和耐受性。
  • 索拉非尼治疗时需关注腹泻和手足皮肤反应,SIRT治疗时需关注疲乏等不良反应。

局限性

  • 开放标签设计可能影响生活质量和不良事件的评估。
  • SIRT组有22%患者未接受SIRT,其中49%接受了索拉非尼治疗,可能稀释意向治疗分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma. We aimed to compare the efficacy and safety of sorafenib to that of selective internal radiotherapy (SIRT) with yttrium-90 (90Y) resin microspheres in patients with hepatocellular carcinoma. METHODS: SARAH was a multicentre, open-label, randomised, controlled, investigator-initiated, phase 3 trial done at 25 centres specialising in liver diseases in France. Patients were eligible if they were aged at least 18 years with a life expectancy greater than 3 months, had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Child-Pugh liver function class A or B score of 7 or lower, and locally advanced hepatocellular carcinoma (Barcelona Clinic Liver Cancer [BCLC] stage C), or new hepatocellular carcinoma not eligible for surgical resection, liver transplantation, or thermal ablation after a previously cured hepatocellular carcinoma (cured by surgery or thermoablative therapy), or hepatocellular carcinoma with two unsuccessful rounds of transarterial chemoembolisation. Patients were randomly assigned (1:1) by a permutated block method with block sizes two and four to receive continuous oral sorafenib (400 mg twice daily) or SIRT with 90Y-loaded resin microspheres 2-5 weeks after randomisation. Patients were stratified according to randomising centre, ECOG performance status, previous transarterial chemoembolisation, and presence of macroscopic vascular invasion. The primary endpoint was overall survival. Analyses were done on the intention-to-treat population; safety was assessed in all patients who received at least one dose of sorafenib or underwent at least one of the SIRT work-up exams. This study has been completed and the final results are reported here. The trial is registered with ClinicalTrials.gov, number NCT01482442. FINDINGS: Between Dec 5, 2011, and March 12, 2015, 467 patients were randomly assigned; after eight patients withdrew consent, 237 were assigned to SIRT and 222 to sorafenib. In the SIRT group, 53 (22%) of 237 patients did not receive SIRT; 26 (49%) of these 53 patients were treated with sorafenib. Median follow-up was 27·9 months (IQR 21·9-33·6) in the SIRT group and 28·1 months (20·0-35·3) in the sorafenib group. Median overall survival was 8·0 months (95% CI 6·7-9·9) in the SIRT group versus 9·9 months (8·7-11·4) in the sorafenib group (hazard ratio 1·15 [95% CI 0·94-1·41] for SIRT vs sorafenib; p=0·18). In the safety population, at least one serious adverse event was reported in 174 (77%) of 226 patients in the SIRT group and in 176 (82%) of 216 in the sorafenib group. The most frequent grade 3 or worse treatment-related adverse events were fatigue (20 [9%] vs 41 [19%]), liver dysfunction (25 [11%] vs 27 [13%]), increased laboratory liver values (20 [9%] vs 16 [7%]), haematological abnormalities (23 [10%] vs 30 [14%]), diarrhoea (three [1%] vs 30 [14%]), abdominal pain (six [3%] vs 14 [6%]), increased creatinine (four [2%] vs 12 [6%]), and hand-foot skin reaction (one [<1%] vs 12 [6%]). 19 deaths in the SIRT group and 12 in the sorafenib group were deemed to be treatment related. INTERPRETATION: In patients with locally advanced or intermediate-stage hepatocellular carcinoma after unsuccessful transarterial chemoembolisation, overall survival did not significantly differ between the two groups. Quality of life and tolerance might help when choosing between the two treatments. FUNDING: Sirtex Medical Inc.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017. PMID: 29107679. doi:10.1016/S1470-2045(17)30683-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。